(Q24681480)
Statements
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) (English)
0 references
1 January 2007
0 references
109
0 references
31-9
0 references
1
0 references
1 reference
1 reference